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SUMMARY34
Infections by protozoan parasites, such as Plasmodium falciparum or Leishmania donovani, have a35
significant health, social, and economic impact and threaten billions of people living tropical and sub-36
tropical regions of developing countries worldwide. The increasing range of parasite strains resistant37
to frontline therapeutics makes the identification of novel drug targets and the development of38
corresponding inhibitors vital. Post-translational modifications (PTMs) are important modulators of39
biology and inhibition of protein lipidation has emerged as a promising therapeutic strategy for40
treatment of parasitic diseases. In this review we summarise the latest insights into protein lipidation41
in protozoan parasites. We discuss how recent chemical proteomic approaches have delivered the42
first global overviews of protein lipidation in these organisms, contributing to our understanding of43
the role of this PTM in critical metabolic and cellular functions. Additionally, we highlight the44
development of new small molecule inhibitors to target parasite acyl transferases.45
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INTRODUCTION49
Infections with protozoan parasites of the genera Plasmodium, Leishmania, Toxoplasma, and50
Trypanosoma are among the most prevalent diseases in developing countries. Transmission of51
Plasmodia to human hosts through the bites of infected female Anophelesmosquitoes results in the52
acute febrile illness malaria. In 2015, 95 countries reported ongoing transmissions, resulting in half of53
the worlds population (3.2 billion people) being at risk of malaria. P. falciparum and P. vivax pose the54
greatest threats with P. falciparum being responsible for most malaria-related deaths and P. vivax55
being the most dominant malaria parasite outside of sub-Saharan Africa (WHO, 2015). Protozoan56
parasites of the genus Leishmania, transmitted by the female sand fly, cause the spectrum of57
diseases known as the Leishmaniases. Symptoms range from skin ulcers with permanent scars to the58
swelling of the spleen and liver. Leishmaniases have been reported in Asia, Africa, South and Central59
America, and southern Europe, with 20-30,000 deaths annually (WHO, 2016a). Toxoplasmosis results60
from an infection with Toxoplasma gondii, transmitted through poorly cooked food, excrements61
from infected animals, or during pregnancy. Although up to half of the worlds population becomes62
infected at some point in their lives, the immune system can usually cope with the parasite (Flegr et63
al., 2014). However, toxoplasmosis can cause miscarriage during pregnancy or cause serious64
infections of the lungs or brain in people with a weak immune system (Jones et al., 2014). Another65
well-known disease caused by a protozoan parasite is human African trypanosomiasis (HAT) which is66
caused by Trypanosoma brucei. Also known as sleeping sickness, HAT is transmitted by the tsetse fly67
and occurs in 36 sub-Saharan African countries (WHO, 2016b). These diseases have serious and68
sometimes lethal consequences if untreated. One major challenge is the increasing number of strains69
that have developed resistance against frontline therapeutics, including chloroquine,70
pyrimethamine/sulfadoxine, and artemisinin in the case of malaria (Sinha et al., 2014; Mbengue et71
al., 2015), pentavalent antimonials in the case of Leishmaniasis (Hajjaran et al., 2016), and72
melarsoprol and pentamidine in the case of HAT (Baker et al., 2013; Graf et al., 2016). This highlights73
an urgent need for new validated drug targets and lead compounds.74
Post-translational modifications (PTMs) are covalent and predominantly enzymatic modifications of75
proteins that occur during or after protein translation. One such PTM is the attachment of lipids (e.g.76
myristic or palmitic acid) to protein N-termini or side chains. Lipidation is typically catalysed by an77
acyl transferase that utilises the coenzyme A activated lipid as a cofactor. In this review we will focus78
on two protein lipidations: S-acylation, the attachment of a long chain saturated fatty acid (mainly79
C16:0, palmitate) to a cysteine side chain via a thioester linkage, and N-myristoylation. N-80
Myristoylation is catalysed by an acyl transferase, N-myristoyl transferase (NMT), which attaches81
myristic acid to the N-terminus of a specific set of protein substrates in lower and higher eukaryotes,82
thereby forming an amide bond between the 14-carbon saturated fatty acid and an N-terminal83
glycine (Boutin, 1997). The corresponding PTM occurs co-translationally (Wilcox et al., 1987) and is84
generally known to be involved in protein-protein interactions, the association of proteins with85
membranes, and protein stability (Resh, 1999, 2006; Wright et al., 2009). Until recently, relatively86
little was known about the protein substrates of NMT in protozoan parasites. In P. falciparum, a87
single NMT isoform was discovered that was shown to myristoylate GAP45 (host cell invasion; (Rees-88
Channer et al., 2006)), CDPK1 (life cycle regulation; (Möskes et al., 2004)), ARF1 (trafficking; (Leber et89
al., 2009)) and AK2 (energy metabolism; (Rahlfs et al., 2009)). In Leishmania, ARL1 (trafficking; (Sahin90
et al., 2008)), HASPB (unknown function; (Sádlová et al., 2010)) and PPEF (protein phosphatase;91
(Mills et al., 2007)) have been reported to be myristoylated, amongst others. Our understanding of92
the significance of this PTM has been greatly enhanced over the last five years by global chemical93
proteomic strategies, as discussed in the next two sections (APPROACHES FOR GLOBAL PROFILING94
OF PROTEIN LIPIDATION and APPLICATION OF GLOBAL LIPIDATION MAPPING TOOLS IN PARASITES).95
NMT had been identified as a likely essential protein and potential drug target as early as 2000 by96
Holder et al. for P. falciparum (Gunaratne et al., 2000) and 2003 by Price et al. for L. major and T.97
brucei (Price et al., 2003). Since then, a variety of different small molecule inhibitors have been98
reported, and recent developments will be discussed in the last section (INHIBITORS OF PROTEIN99
LIPIDATION IN PROTOZOAN PARASITE).100
Chemical proteomic approaches have also recently revealed widespread protein S-acylation in101
protozoan parasites. Palmitoylacyltransferases (PATs) catalyse S-acylation but the consensus102
sequence for this modification is even more poorly defined than that for N-myristoylation, the103
substrate specificities of the multiple PATs in any one organism are not entirely defined. The104
dynamic, reversible nature of some S-acylation events makes unravelling the state and function of105
this modification particularly challenging. PATs are integral membrane proteins with a characteristic106
DHHC motif within a cysteine-rich domain (CRD) important for catalysis. They localise to membranes107
of different subcellular compartments via targeting motifs that are not yet understood, and that108
differ between species. There are 12 PATs in P. falciparum, 11 in the rodent model Plasmodium109
berghei, and 18 in T. gondii, some of which appear to be essential for parasite survival (Frénal et al.,110
2013). Furthermore, several recent studies indicate that PATs play stage-specific roles in parasite111
biology (Beck et al., 2013; Santos et al., 2016; Hopp et al., 2016; Tay et al., 2016). In trypanosomatids,112
bioinformatic searches for the DHHC-CRD motif have identified 12 predicted PATs in T. brucei113
(Emmer et al., 2009), 15 in T. cruzi, and 20 in L. major (Goldston et al., 2014). Interestingly, RNAi114
knockdown of individual PATs does not affect T. brucei parasite growth in culture, and although this115
does not exclude a role in virulence or infection, this suggests that there is redundancy and cross-116
over in PAT substrate specificity (Emmer et al., 2011). The study of PAT function is hindered by the117
fact that, in contrast to N-myristoylation, there are no specific chemical inhibitors of PATs. The118
druggability of these enzymes should be a high priority for further study.119
120
APPROACHES FOR GLOBAL PROFILING OF PROTEIN LIPIDATION121
A given PTM is typically of low abundance and often very difficult to detect and quantify directly in122
the context of a whole proteome. Modified proteins are therefore usually enriched before123
downstream analysis. However, there are no reliable affinity-based methods to globally enrich124
lipidated proteins, and historically lipidation has been studied on a protein-by-protein basis using125
metabolic labelling with poorly-sensitive radiolabelled lipid analogues in conjunction with126
immunoprecipitation. Either specific and highly sensitive antibodies are required, making the127
approach low-throughput, or the protein of interest must be overexpressed, raising questions over128
the validity of the result in native systems. Computational approaches to predict lipidation of129
proteins also exist (Maurer-Stroh et al., 2002; Bologna et al., 2004; Ren et al., 2008). However, the130
sequence motifs are not clearly defined and bioinformatics tools rely on learning sets derived from131
species such as yeast that may not be transferable to protozoan parasites.132
Here we discuss two modern techniques that have been effectively applied in protozoan parasites to133
globally enrich and identify lipid modified proteins. The first exploits the chemistry of the PTM134
linkage, and the second uses tagged lipid analogues that are metabolically incorporated into proteins135
in the cell. Both approaches have benefited hugely from parallel advances in quantitative proteomics136
methods and the increasing sensitivity of mass spectrometry (MS) instruments.137
Acyl biotin exchange (ABE) chemistry is a well-established technique for detecting S-acylation of138
proteins (Roth et al., 2006). ABE is a biotin-switch method that exploits our ability to selectively139
capture thiols and cleave thioesters to install a biotin affinity tag onto proteins at the site of S-140
acylation. A protein lysate is treated with a thiol-reactive reagent such as N-ethyl maleimide (NEM) to141
block free thiols. Subsequently, thioesters (including S-acyl chains) are selectively cleaved with142
hydroxylamine (HA; Fig. 1). Treatment with the disulphide-forming reagent HPDP-biotin labels the143
liberated thiols with biotin. A control portion of the lysate is not treated with HA, and therefore lacks144
the biotin tag. The two samples are then incubated with an affinity resin (e.g. avidin agarose) and145
enriched proteins subjected to proteolytic digest. The corresponding peptide fragments are146
identified by mass spectrometry-based proteomics and the hits of the two samples are compared.147
The disulfide linkage between the biotin group and the modified peptide can also be cleaved to148
enable identification of the S-acylation site. Variations on this technique include acyl-RAC (resin-149
assisted capture) (Forrester et al., 2011), where newly exposed thiols derived from thioesters are150
directly captured on a resin  combining the labelling and enrichment steps  and the recently151
reported acyl-PEG exchange (APE) (Percher et al., 2016), which installs a polyethylene glycol (PEG)152
tag in place of biotin; the mass shifts from the PEG group are readily detectable through gel153
electrophoresis and Western blot, and can be used to determine levels of S-acylation.154
ABE and related approaches are powerful methods for profiling S-acylation. However, ABE provides155
no information on the nature of the PTM that was incorporated at the thioester site (such as the acyl156
chain length), is limited to thioester-linked fatty acylations, and cannot distinguish acylation from any157
other thioester-linked modifications. Incomplete blocking of thiols of abundant proteins can also158
cause problems of background noise. Metabolic tagging with click chemistry (MTCC) is a159
complementary approach that is more generally applicable to a variety of lipid modifications (Tate et160
al., 2015).161
The principle behind MTCC is to use the endogenous machinery of the cell to install a latent chemical162
tag via the PTM: tagged analogues of the PTM of interest are fed to live cells and incorporated into163
modified proteins (Fig. 2). The tag must be very small in order to be tolerated by the enzymes that164
catalyse modification, biorthogonal such that it reacts minimally with the cellular environment, yet165
reactive enough to act as a chemical handle for downstream capture (with fluorophores or affinity166
handles such as biotin) and analysis of tagged proteins. The capture chemistry most widely used is167
the copper-catalysed ligation of a terminal alkyne with an azide (a click reaction, also referred to as168
CuAAC). Although both azido- and alkynyl-fatty acids have been used in metabolic tagging169
approaches, alkyne-modified lipids are often preferred  mainly due to the empirical observation170
that this orientation (alkyne on lipid, azide on capture reagent) leads to lower background labelling.171
MTCC has been applied to detect N-myristoylation and S-palmitoylation of proteins in protozoan172
parasites, using the tools shown in Figure 2.173
A significant advantage of MTCC is that in principle a tool can be designed to address any PTM in an174
unbiased way. For example, a myristic acid mimic such as YnMyr (1) or AzMyr (3) (Fig. 2B) could be175
incorporated onto protein N-termini (as for NMT-catalysed N-myristoylation), or onto other sites,176
such as S-acylation sites. Tagged analogues should therefore enable detection of less common lipid177
modifications, such as lysine myristoylation. However, identification of the site of modification can178
be complex because the biotin-lipid-peptide fragment resulting from protein digest is difficult to179
detect by mass spectrometry, or remains anchored to the resin if the proteins are digested on-bead.180
To tackle this problem, several groups have developed cleavable biotin-azide reagents that allow181
selective release of the lipidated peptide (e.g. (Broncel et al., 2015)). The extent to which lipid182
analogues are metabolised by the biological system is difficult to assess and remains largely183
unexplored; this complicates analysis but also provides opportunities to use these tools to map lipid184
metabolism in diverse systems in the future. As we shall illustrate in the next section, combining ABE185
and/or MTCC with specific chemical inhibitors or genetic knockdowns of lipid transferase enzymes186
has proven to be a particularly powerful approach for globally identifying lipidated proteins and187
assessing the druggability of their cognate transferases.188
189
APPLICATION OF GLOBAL LIPIDATION MAPPING TOOLS IN PARASITES190
Over the past 5 years, both ABE and MTCC have been applied in parasites to discover and validate191
protein lipidation and to probe its inhibition. Prior to the development of these techniques only a192
handful of proteins had been shown to be lipidated in these organisms, and in many cases only using193
genetically engineered over-expression systems (reviewed in (Tate et al., 2014). Here we discuss194
recent applications of these techniques in apicomplexan parasites (Plasmodia, Toxoplasma) and in195
trypanosomatids (Trypanosoma, Leishmania).196
197
Malaria parasites198
In 2012, Jones et al. reported the first global study of S-palmitoylation in the asexual stage of the199
malaria parasite P. falciparum, by applying both MTCC with the well-established palmitate analogue200
17-ODYA (4) (Fig. 2) and ABE (Jones et al., 2012). Quantitative comparison between sample and201
control in both approaches was carried out using SILAC (stable isotope labelling of amino acids in202
culture) and the study identified >400 potential palmitoylated proteins. The authors combined ABE203
with the compound 2-bromopalmitate (2-BP) to analyse the degree to which specific palmitoylations204
are dynamic. A significant caveat to these results is that 2-BP is not a specific thioesterase inhibitor205
and has broad non-specific reactivity, including particularly on lipid metabolic pathways (Coleman et206
al., 1992; Zheng et al., 2013; Davda et al., 2013); the continued use of this molecule despite its207
potent promiscuity is symptomatic of the lack of well-characterised specific inhibitors for208
palmitoyltransferases. Despite this issue, the study of Jones et al. was nevertheless a landmark209
application of ABE and MTCC in a protozoan parasite, and elegantly demonstrates the210
complementarity of the two techniques (Fig. 3A).211
Our lab and others have worked extensively on N-myristoylation in malaria and other biological212
systems, both in terms of inhibitor development (see section INHIBITORS OF PROTEIN LIPIDATION IN213
PROTOZOAN PARASITES) and to globally identify myristoylated proteins. MTCC relies on the cellular214
machinery to take up fatty acid analogues, convert them into substrates for the acyl transferase (the215
acyl-CoA thioesters) and incorporate them enzymatically. Early work demonstrated that NMTs will216
accept azide- and alkyne-tagged myristate mimics in vitro and incorporate them into peptide217
substrates (Heal et al., 2008). Furthermore, the binding mode of YnMyr-CoA crystallised in the active218
site of P. vivax NMT (Fig. 4A) is nearly identical to the conformation adopted by Myr-CoA (Wright et219
al., 2014). MTCC with YnMyr (1) was applied to identify myristoylated proteins in asexual stage P.220
falciparum schizonts, revealing not only putative N-myristoylated proteins but also proteins known221
to be modified with a glycosylphosphatidylinositol(GPI) anchor (Fig. 4B). Jones et al. found that 17-222
ODYA (4) is also incorporated into Plasmodium GPI anchors (Jones et al., 2012). These results are not223
surprising, since Plasmodium GPI anchors are known to incorporate both fatty acids, and illustrate224
the versatility of the lipid analogues which are readily incorporated by the GPI biosynthetic225
machinery. N-Myristoylation is thought to take place mostly on the N-terminal glycine of substrate226
proteins. To confirm that YnMyr (1) was attached to these sites, a cleavable azido-biotin reagent227
(Broncel et al., 2015) was used: after pull-down of tagged and biotin labelled proteins, tryptic digest228
released both the unmodified and modified peptides (Fig. 2A) (Wright et al., 2014). Indeed, around229
30 modified protein N-termini were detected in this case, providing conclusive evidence for the site-230
specific attachment of YnMyr (1) to these proteins.231
Identifying the mode of action of drugs and small molecules of interest in a live cell context is very232
challenging, particularly in protozoan parasites. We next exploited our robust and rapid MTCC233
approach to assess whether NMT inhibitors were acting on-target in the parasite, using both234
previously reported T. brucei inhibitors (Fig. 10A, compounds 19 and 20) (Frearson et al., 2010; Brand235
et al., 2012) and a novel chemically distinct series developed in-house (Fig. 9A, compounds 15 and236
analogues) (Rackham et al., 2014). All five compounds specifically inhibited incorporation of YnMyr237
(1) into N-myristoylated proteins, and furthermore the in-cell dose-responses calculated from levels238
of YnMyr (1) incorporation correlated well with EC50 for parasite growth inhibition (Fig. 4C). These239
experiments therefore demonstrated direct engagement of compounds with NMT in cells and linked240
parasite death to loss of substrate protein myristoylation. With validated tools in-hand, the241
phenotype of NMT inhibition in the malaria parasite could be characterised (Wright et al., 2014).242
YnMyr (1) has proven a versatile tool in Plasmodium species, and this analogue has also been applied243
in the mouse malaria parasite P. berghei to detect myristoylation of specific proteins involved in244
sexual development: two inner-membrane complex proteins (Poulin et al., 2013), and two protein245
phosphatases (Guttery et al., 2014).246
247
Toxoplasma gondii248
Palmitoylation has been implicated in the intracellular life cycle of the related apicomplexan parasite249
T. gondii. For example, a palmitoyl protein thioesterase was identified as a target for a small250
molecule enhancer of host cell invasion, suggesting that dynamic protein S-acylation may play an251
important regulatory role in this process (Child et al., 2013). The latter study also used 17-ODYA (4)252
(Fig. 2B) to verify S-palmitoylation of specific proteins associated with the enhanced invasive253
phenotype. Building on this work, Foe et al. carried out a global analysis of 17-ODYA (4) tagged254
proteins in T. gondii extracellular invasive stages (Foe et al., 2015). Recognising that the lipid probe255
may be incorporated into multiple sites in addition to S-palmitoylated cysteines (such as GPI256
anchored proteins), the authors also compared samples treated with or without hydroxylamine (HA).257
This treatment should selectively cleave thioesters, releasing only S-acylation sites. Quantitative258
label-free proteomics was used to generate hits within these two experimental set-ups. Comparing259
the results revealed a final list of ~280 high confidence S-palmitoylated proteins in T. gondii. Follow-260
up analysis of one newly identified S-palmitoylated protein, AMA1, which is known to be associated261
with invasion, showed that one cysteine in particular is likely S-acylated. S-Acylation did not appear262
to be related to AMA1 localisation, but a subtle effect on the rate of secretion of microneme proteins263
was observed. Interestingly, the S-palmitoylated proteome of T. gondii showed limited overlap with264
palmitoylated orthologues in P. falciparum, perhaps reflecting differences in the life stages analysed,265
or indicating that most palmitoylation is organism-specific (Foe et al., 2015).266
The complementary approach of ABE was also recently applied to T. gondii. Semi-quantitative267
comparisons of samples treated with and without HA resulted in >400 protein hits (Caballero et al.,268
2016). Around half of these were also identified by Foe et al. using their complementary approach269
(Fig. 3B). Although only around 50 of the proteins identified by Caballero et al. were found in two270
biological replicates, suggesting that there is quite some variability in the ABE technique, again271
around half matched to high confidence hits from Foe et al. (Supplementary Table S1). Together,272
these two studies have provided a wealth of data on potential palmitoylated proteins in T. gondii.273
274
Comparisons across the Apicomplexa275
Foe et al. compared their T. gondii palmitome dataset (17-ODYA (4)) with the P. falciparum datasets276
(17-ODYA (4) plus ABE) of Jones et al. by identifying orthologues in these two related species. They277
noted a poor overlap. We added the data of Caballero et al. to this analysis, comparing the aggregate278
of all three studies: Of ~320 putative palmitoylated proteins identified in P. falciparum that have T.279
gondii orthologues, 141 now have some evidence for S-acylation from either ABE or 17-ODYA (4)280
analyses in T. gondii (Fig. 3C). As has been noted by the studies described above, it is clear that MTCC281
and ABE identify not only overlapping but also distinct subsets of the palmitome (and therefore also282
distinct sets of false positives), and there is value to using both methodologies in combination. In283
addition, by comparing the P. falciparum data from our myristoylation study with the palmitoylation284
analyses, we identify 10 likely dually acylated proteins in the parasite (Fig. 3D). The Apicomplexa285
comparisons are given in Supplementary Table S1, although it should be noted that exact numbers in286
these comparisons are dependent on how the analysis is carried out: orthologues frequently do not287
map one-to-one and mass spectrometry data often cannot distinguish between closely related288
proteins, which is a widely studied problem in protein inference (Li and Radivojac, 2012).289
290
Trypanosoma brucei291
MTCC was first applied in the sleeping sickness parasite T. brucei to validate the N-myristoylation of a292
particular protein of interest, ARL6 (Price et al., 2012), which had a putative role in intracellular293
protein trafficking. Following metabolic tagging with YnMyr (1) (Fig. 2B), ARL6 was294
immunoprecipitated from lysate with a specific antibody. Subsequent labelling with a fluorescent295
azide reagent allowed detection of the modified ARL6 in-gel. Expanding this approach, a global296
profile of N-myristoylated proteins was performed comparing both bloodstream and insect stages of297
T. brucei (Fig. 5A) (Wright et al., 2016). Out of ~100 robustly enriched proteins in each life stage,298
roughly half possessed the canonical N-terminal glycine myristoylation motif. Others are known to be299
GPI anchored or S-acylated, consistent with the frequent observation that S-acylation is more300
permissive of fatty acid chain length in many eukaryotic systems  i.e. both myristate and palmitate301
(and their corresponding alkynyl-analogues) can be incorporated onto cysteine side chains (Fig. 5B).302
Indeed, longer chain palmitate analogue YnPal (2) tagged a distinct but overlapping set of proteins in303
T. brucei (Wright et al., 2016). Comparison of the MTCC-derived dataset with the results of an earlier304
ABE experiment conducted in T. brucei by Emmer et al. (Emmer et al., 2011) revealed some overlap305
but also differences (Fig. 6A); these are likely the result of both biological (host versus insect form306
parasites) and technical (MTCC versus ABE) differences in the two studies. Interestingly, YnMyr (1)307
turned out to be toxic at extended incubation times to bloodstream but not insect forms of T. brucei308
(Wright et al., 2016). This observation is not without precedent (Doering et al., 1994) and is likely309
related to effects on the GPI anchor pathway, which is highly dependent on myristate incorporation310
and crucial for T. brucei host stages (Ferguson et al., 1985).311
Unlike for S-acylation where multiple, possibly redundant, palmitoylacyltransferase (PAT) enzymes312
exist, NMT appears to be the sole enzyme responsible for protein N-myristoylation. The enzyme has313
a quite narrow substrate specificity for myristoyl-CoA and closely related analogues (Wright et al.,314
2009). Furthermore, whilst there are no specific chemical tools for the inhibition of PATs, for NMT315
there are several well-characterised molecules available (see section INHIBITORS OF PROTEIN316
LIPIDATION IN PROTOZOAN PARASITE). The T. brucei NMT inhibitors reported by Frearson et al.317
(Frearson et al., 2010; Brand et al., 2012) specifically reduced YnMyr incorporation into N-318
myristoylated, but not GPI anchored proteins in BSF parasites (Fig. 5B), demonstrating target319
engagement in cells. We therefore applied these compounds to simplify the interpretation of the320
complex YnMyr (1) tagged proteome data, and determine which proteins were true NMT substrates.321
Parasites were treated with different concentrations of two inhibitors with very different potency,322
and then proteins tagged with YnMyr (1). After enrichment, quantitative label-free proteomics was323
used to assess which proteins had reduced YnMyr (1) incorporation in response to inhibition. This324
analysis revealed ~50 high confidence NMT substrates; for many of these the YnMyr (1)-modified N-325
terminal glycine-containing peptide was also identified via cleavable reagents.326
327
Trypanosoma cruzi328
NMT is also under investigation as a potential drug target in T. cruzi. Although NMT inhibitors329
developed against T. brucei were significantly less efficacious in this organism, Roberts et al. showed330
that the compounds inhibited parasite growth and reduced incorporation of azido-myristate mimic331
AzMyr (3) (Fig. 2B) in a dose-dependent manner (as read-out by in-gel fluorescence), suggesting that332
NMT is druggable in this system (Roberts et al., 2014). The authors recently followed this with a333
study applying AzMyr (3) to identify N-myristoylated proteins in T. cruzi (Roberts and Fairlamb,334
2016). They used both label-free and SILAC quantification and focused on N-myristoylation by335
treating samples with HA to cleave S-acylation sites. Additionally, they applied two concentrations of336
their well-characterised NMT inhibitor. This analysis identified ~50 high confidence N-myristoylated337
proteins in the parasite; more than half of these had homologues identified as NMT substrates in the338
T. brucei YnMyr study (Wright et al., 2016) (Fig. 6B). Related compounds were also recently shown to339
act on-target in T. cruzi using a gel-based fluorescent read-out after AzMyr (3) tagging (Herrera et al.,340
2016).341
342
Leishmania donovani343
The extent of protein lipidation in Leishmania species was similarly poorly characterised until344
recently. We applied YnMyr (1)-based MTCC with label-free quantitative proteomics to assess the345
potential of NMT as a drug target in L. donovani (Wright et al., 2015). As in T. brucei, YnMyr (1) was346
incorporated into likely N-myristoylated, S-acylated and GPI anchored proteins, as well as into347
surface glycolipids that are prevalent in trypanosomatids. A quantitative chemical proteomics based348
comparison of YnMyr (1) tagged proteins revealed an overlap of 67% between insect (promastigote)349
and mammalian host (amastigote) stages of Leishmania parasites, a reflection of their distinct350
metabolism, and proteome profiles. In addition to enabling study of the different life stages ex vivo,351
the high sensitivity of MTCC even allowed detection of YnMyr (1) incorporation into native levels of352
the well-studied N-myristoylated protein HASPB in macrophages infected with amastigotes.353
Taking a similar approach to T. brucei, the effects of NMT inhibition on YnMyr (1) modification of354
each protein were assessed using inhibitor 19 and its N-methylated analogue (19a). These two355
compounds have nM potency against LdNMT but dramatically different potencies in cells, with the356
latter (19a) nearly 50-fold more active against amastigotes than the former (19). Whilst this357
discrepancy could be due to compound uptake, metabolism, or efflux, it also raised the question of358
whether both compounds were truly acting on-target. YnMyr (1) tagging was performed in the359
presence of the two compounds at approximately their EC50 values, and revealed the same loss of360
labelling of specific bands (Fig. 7A). Further quantitative chemical proteomics confirmed this result:361
YnMyr (1) tagging of the same group of proteins was sensitive to NMT inhibition, demonstrating that362
both inhibitors engage NMT in live cells. As in other systems, combining chemical inhibition and363
MTCC proved a powerful approach for dissecting the complex lipidation patterns and ~30 proteins364
were identified as high confidence NMT substrates (Fig. 7B). In addition to proteins involved in365
trafficking, protein phosphorylation, Golgi function and proteasomal degradation, just over half of366
the hits are completely uncharacterised. Again, there was good overlap with high confidence T.367
bruceimyristoylated orthologues (Fig. 6C).368
Based on this study, it is clear that on-target NMT inhibitors selectively reduce YnMyr (1)369
incorporation into specific proteins, but do not affect tagging of others (GPI anchored, S-acylated).370
Indeed, we observed this across Plasmodia, Trypanosoma, and Leishmania parasites, as described371
above. Since YnMyr (1) incorporation can be assessed on-gel, MTCC provides a rapid method to372
screen for on-target activity of promising NMT inhibitors in these organisms.373
374
Comparisons across the trypanosomatids375
The three studies analysing N-myristoylation using MTCC in T. brucei, T. cruzi, and L. donovani, all376
applied well-characterised inhibitors from the series reported by Frearson et al. in quantitative377
proteomics experiments to define NMT substrates. This is important because it enables one to378
distinguish between proteins that incorporate Yn/AzMyr (1/3) at S-palmitoyl or other sites, from379
those truly N-terminally myristoylated by NMT. With this piece of information and the T. brucei S-380
palmitoyl proteomics studies of Wright et al. (YnPal MTCC) and Emmer et al. (ABE), candidate381
proteins for dual acylation in this organism can be identified (Fig. 6D and Supplementary Table S2).382
This analysis confirms well-validated examples (e.g. dual acylation of metacaspase 4 and the family of383
flagellar calcium-binding proteins (Godsel, 1999; Proto et al., 2011)) and reveals further avenues of384
study. For example, the data suggest dual acylation of an ADP-ribosylation factor, two protein385
phosphatases, and numerous proteins involved in fatty acid metabolism, although whether the latter386
are acylated or bind lipids as part of their catalytic activity remains to be investigated.387
To identify conserved N-myristoylated proteins, the set of high confidence T. brucei NMT hits were388
analysed for orthologues in T. cruzi and L. donovani and cross-compared with N-myristoyl datasets389
from those organisms. There was indeed good overlap between datasets (Fig. 6B & C,390
Supplementary Table S2), perhaps due to similarity in experimental protocols, as well as the close391
relatedness of the organisms. The 10 proteins identified across all three organisms (Fig. 6E) are likely392
only a snapshot of the conserved N-myristoylated proteome, but proteins with functions as diverse393
as protein degradation (the proteasome subunit), phosphorylation (two protein phosphatases),394
trafficking (two ARFs), and metabolic regulation (AMPK subunit) can be identified.395
396
INHIBITORS OF PROTEIN LIPIDATION IN PROTOZOAN PARASITES397
Considering that acyl transferases catalyse the attachment of modifications that are essential for398
several vital biological processes in protozoan parasites, the development of corresponding selective399
and potent small molecule inhibitors could significantly contribute to the limited arsenal of therapies400
currently available. During the last decade, a variety of different small molecule inhibitors has been401
identified. The last few years have seen further development of the corresponding scaffolds, as402
summarised below.403
404
Plasmodium and Leishmania405
In order to identify P. falciparum and P. vivax NMT (PfNMT and PvNMT) inhibitor scaffolds, two high406
throughput screening (HTS) approaches were performed. For the first HTS a 150000 compound407
library was screened with our collaborators at Pfizer in a radioactive scintillation proximity assay408
(SPA) against PfNMT and Leishmania donovani NMT (LdNMT) (Bell et al., 2012), while a second HTS409
was performed in collaboration with MRC Technology (MRCT) and used a 60,000 compound library in410
a fluorescence based assay against PvNMT (Goncalves et al., 2012b). The fluorescence-based assay411
format exploits the reaction between the thiol reactive 7-diethylamino-3-(4-maleimido-phenyl)-4-412
methylcoumarin (CPM) and the free CoA liberated during the enzymatic acyl-transfer (Goncalves et413
al., 2012a). Both high throughput screens identified hits in a variety of structural series. Thereby, the414
SPA based HTS resulted in the identification of excellent PfNMT inhibitor scaffolds that were further415
progressed during the last four years. The most promising hit compound of the MRCT HTS was416
further progressed in a compound series based on a quinoline scaffold (Fig. 8A, compound 5)417
characterised by micromolar IC50 against PvNMT and a moderate selectivity over human NMT418
(HsNMT) (Goncalves et al., 2012b). The HTS of the Pfizer library against LdNMT successfully419
identified four series (Fig. 8B aminoacylpyrrolidines  compound 7, piperidinylindoles  compound 8,420
thienopyrimidines, and biphenyl derivatives) with good to excellent selectivity over all other NMTs421
tested (Bell et al., 2012). The binding mode of all four inhibitor classes was subsequently determined422
by co-crystallisation with LdNMT and/or L. major NMT (LmNMT) (Fig. 8B; (Brannigan et al., 2014). All423
inhibitors, apart from the aminoacylpyrrolidines, interact via a basic centre with the C-terminal424
carboxylate of the enzyme. In the case of 7 and 9, the corresponding interaction is mediated by the425
hydroxyl substituent. Moreover, all compounds show significant interactions with aromatic side426
chains of Phe90, Tyr217, and Tyr345, and exhibit an additional set of individual interactions. These427
structural insights were used in a subsequent structure-guided fusion of scaffolds 7 and 8 (Hutton et428
al., 2014). The product (Fig. 8B, compound 9) of the inhibitor hybridization exhibits a 40-fold429
increased potency with good selectivity over HsNMT. However, one major issue with all three430
inhibitors (7, 8, and 9) is the lack of cell based activity, which MTCC analysis suggests is due to poor431
cellular uptake limiting access to the target in cells (Hutton et al., 2014; Paape et al., 2014).432
In parallel an alternative strategy was exploited to identify new PfNMT inhibitors by testing the433
antimalarial potency of drug molecules that have already been evaluated by pharma companies as434
lead compounds for the treatment of other diseases. This so called piggyback approach was based435
on a library of 43 inhibitors against NMT from Candida albicans (CaNMT). Although four hits436
successfully reduced parasitaemia in vitro, the compounds exhibit a low ligand efficiency (LE) due to437
their high molecular weight and high lipophilicity relative to their low enzyme affinity (Bowyer et al.,438
2007, 2008). Screening a second small library of 25 inhibitors of CaNMT and Trypanosoma brucei439
NMT (TbNMT) finally revealed RO-09-4609 (10) as a moderately selective hit compound. Further440
optimisation resulted in the development of an inhibitor series with a benzo[b]furan scaffold (Fig. 9A,441
compound 11+12) that exhibits a 100-fold affinity improvement over the initial compound. Co-442
crystallisation of inhibitor 12 with P. vivax NMT (PvNMT) revealed a competitive binding mode of the443
benzo[b]furan inhibitors with the peptide substrate (Yu et al., 2012). The corresponding inhibitors444
are characterised by moderate enzyme affinity, and the LE was still too low to consider the series to445
be favourable for further optimisation. To overcome this issue, an inhibitor series based on a446
benzo[b]thiophene scaffold (Fig. 9A, compounds 13-15 ?ǁĂƐĚĞǀĞůŽƉĞĚƚŽŵĞĚŝĂƚĞŝŵƉƌŽǀĞĚʋ ? ? ? ?
interactions with two tyrosine residues due to the increased aromatic character of the thiophene448
moiety. Crystallography of these novel inhibitors with PvNMT revealed an overlapping but distinct449
binding mode to the benzo[b]furanes, with the benzo[b]thiophene moiety being buried deeper450
within a hydrophobic pocket (Rackham et al., 2013). The structure additionally showed that an451
appropriately positioned methoxyphenyl substituent should be able to interact with Phe105 and452
Ser319 of PvEDd ?ƚŚĞƌĞďǇŝŶĐƌĞĂƐŝŶŐƚŚĞĂĨĨŝŶŝƚǇĚƵĞƚŽĨƵƌƚŚĞƌʋ ?ʋŝŶƚĞƌĂĐƚŝŽŶƐ ?dŚŝƐŚǇƉŽƚŚĞƐŝƐǁĂƐ ? ? ?
validated by increasing the linker length between the benzo[b]thiophene core and the454
methoxyphenyl substituent. The resulting inhibitor 14 exhibits a 6-fold increased affinity against455
PfNMT (Fig. 9A; (Rackham et al., 2014). However, one issue with the ester containing456
benzo[b]thiophenes is the high lipophilic ligand efficiency (LLE) value of e.g. 13.2 for 13. Highly457
lipophilic compounds are more likely to partition from plasma to membranes and proteins and458
thereby exhibit an increased promiscuity and toxicity. The LLE value considers lipohilicity, affinity,459
and molecular size. Thereby, desirable leads exhibit an LLE of <10 (corresponding to LE > 0.3 and460
cLogP < 3) (Keserü and Makara, 2009). To significantly decrease the LLE and to further increase461
enzyme affinity, 1,3,4-oxadiazole was implemented as a bioisosteric replacement of the ester linker462
moiety (Rackham et al., 2014). The corresponding derivatives (Fig. 9A, compound 15) showed a 100-463
fold improved enzyme affinity and a 100-fold decreased lipophilicity while retaining the selectivity464
over HsNMT with respect to the first benzo[b]thiophene lead compound 13. Apart from its465
antiparasitic in vitro activity, compound 15 is potent against four parasite strains, including two drug-466
resistant ones, and shows promising activity against liver stage (EC50 = 372 nM) parasites.467
Scaffold simplification by substituting the bicyclic core with pyridyl (Fig. 5A, compound 16) resulted468
in the most recently reported oxadiazole containing inhibitor series (Yu et al., 2015). Remarkably, the469
scaffold-simplified inhibitors exhibit a similar binding mode in the PvNMT crystal structure as the470
benzo[b]furane derivatives (Fig. 9A). The 1,2,4-oxadiazole is sandwiched between Y334 and Y211,471
while the pyridyl nitrogen of 16 additionally stabilises the enzyme-inhibitor complex via water-472
mediated hydrogen bonds with Y315. Strikingly, the 3-OMe phenyl moiety of compound 16 also473
overlays well with the quinoline scaffold of compound 5 (Fig. 8A). Exchanging the trimethylpyrazole474
with a quinolone moiety finally provided compound 17 (Fig. 9A) with an IC50 of 1.7 nM against PfNMT475
and good cellular efficacy. The benzo[b]thiophene series was also routinely tested against LdNMT.476
Remarkably, the affinity spectrum changes significantly if the bicyclic system is truncated to a477
monocyclic thiophene scaffold (Rackham et al., 2015). Activity against human and Plasmodium NMTs478
decreases by almost two orders of magnitude while affinity against LdNMT increases 8-fold.479
However, since thiophene moieties have been associated with P450 inhibition, a 1,3,4-oxadiazole480
containing 5-chlorophenyl derivative was obtained as optimum scaffold that shows no macrophage481
toxicity. However, the compound failed to inhibit axenic L. donovani amastigotes (leishmanial stage),482
likely due to difficulty accessing the target in this parasite. Therefore, further investigation of the483
physicochemical properties of this series is essential.484
Finally, we also reported development of a PvNMT and LmNMT peptidomimetic inhibitor based on485
an fungal NMT inhibitor (Olaleye et al., 2014). The structure of the peptide (Fig. 9B, compound 18)486
comprises a Ser-Lys dipeptide, a C-terminal cyclohexyl moiety, and an aliphatic chain at the N-487
terminus. The resulting peptidomimetic is characterised by sub-micromolar potency against both488
enzymes and a marginal selectivity over HsNMT. Interestingly, 20% of the electron density of the489
inhibitor-NMT complex structure corresponds to an N-myristoylated inhibitor product and the CoA490
by-product, providing the first direct structural evidence for a product complex in NMT (Fig. 9B). This491
complex is presumably formed in situ in the crystal, favoured by the high inhibitor occupancy in the492
solid state.493
494
Toxoplasma495
S-palmitoylation is a dynamic PTM that requires a corresponding acyl-protein thioesterase (APT) for496
the cleavage of the lipid thioesters. In T. gondii, TgPPT1/TgASH1 was recently identified as an497
orthologue of human APT1. This serine hydrolase can be inhibited by substituted chloroisocoumarin-,498
ɴ ?ůĂĐƚŽŶĞ ? ?ĂŶĚƚƌŝĂǌŽůĞƵƌĞĂ ?ďĂƐĞĚŝŶŚŝďŝƚŽƌƐ ?<ĞŵƉet al., 2013; Child et al., 2013). Interestingly, these499
inhibitors enhance tachyzoite invasion. Although enhancers of invasion are not obvious therapeutic500
agents, Bogyo et al. speculated that the increase in number of host-cells infected by multiple parasites501
and the corresponding increase in the competition for resources within the infected cell might be an502
unconventional point of action for therapeutics, although further studies are required to test this503
hypothesis (Child et al., 2013).504
2-BP is another small molecule compound that is often incorrectly considered a global inhibitor of505
palmitoylation. Treatment of T. gondii with 2-BP resulted in altered gliding motility patterns of the506
parasite and a significant reduction of the invasion process (Alonso et al., 2012), but as mentioned507
above these findings should be interpreted carefully, and in full appreciation of the very promiscuous508
activity and high non-specific toxicity of 2-BP (Davda et al., 2013).509
510
Trypanosoma511
Pyrazole sulphonamides are NMT inhibitors identified in an HTS against Trypanosoma brucei NMT512
(TbNMT) by Wyatt et al. (Frearson et al., 2010). Eight sulphonamide hits of this initial HTS were513
further investigated by Maldonado et al. using high content imaging and a metabolic labelling514
approach. The authors proved the on-target activity of three compounds in sub-micromolar515
concentrations also against T. cruzi NMT with very low cytotoxic side effects (Herrera et al., 2016).516
The lead compound of the HTS, DDD85646 (Fig. 10A, compound 19), shows excellent activity in517
mouse models during the hemolymphatic peripheral infection stage of T. brucei (stage 1) (Brand et518
al., 2012). However, due to a low blood-brain barrier (BBB) permeability, the inhibitor is not active in519
the second stage during which the parasite enters the central nervous system (CNS) thereby giving520
rise to the classic symptoms of sleeping sickness. Therefore, Read et al. prepared modified pyrazole521
sulphonamides with a reduced polar surface and a capped sulphonamide group, significantly522
increasing the BBB permeability (Brand et al., 2014). Their new lead compound (Fig. 10A, compound523
20) demonstrated partial efficacy in stage 2 mouse models. However, one issue is that the increased524
lipophilicity results in off-target effects and poor tolerability of the new lead compound.525
Apart from the pyrazole sulphonamides, Gilbert et al. have progressed two further hits from the526
original HTS and developed a thiazolidinone (e.g. compound 21) and a benzomorpholinone (e.g.527
compound 22) series (Fig. 10A; (Spinks et al., 2015). Like Read et al., the authors aimed at the528
development of BBB permeable NMT inhibitors. Due to a lack of high-resolution structures of TbNMT529
and a very high sequence homology of the binding pockets of TbNMT and LmNMT, the authors used530
LmNMT as surrogate. Co-crystallography of the two new TbNMT inhibitor classes with LmNMT531
revealed that they are characterised by a different binding mode than the sulphonamides (Fig. 10B).532
The lead compound of the thiazolidine series (Fig. 10A, compound 21) is characterised by good533
selectivity over HsNMT, micromolar cellular efficacy, and a good LE value that indicates the potential534
of the series. The benzomorpholinone series (Fig. 10A, compound 22) contains potent antiparasitic535
compounds with cellular potencies in the nanomolar range that exhibit BBB permeable compounds.536
However, the selectivity of the series has to be further improved to enable higher dose levels, and537
thereby maximising the chances of curing stage 2 infections.538
539
CONCLUSIONS540
Protein lipidation is an essential PTM for metabolic and cellular processes in protozoan parasites, and541
its modulation offers interesting opportunities for therapy. Therefore, an extensive investigation of542
the substrates of protozoan acyl transferases and the corresponding downstream effects of their543
inhibition is essential. In this context ABE and MTCC are powerful techniques that can be used to544
profile, image, and identify previously unknown lipidated proteins in a data-driven manner and545
without the need for specific antibodies or protein overexpression. ABE-type approaches can be used546
on any lysate without the need to optimise incorporation of an analogue and without the risk that547
the analogue will perturb the system. However, ABE is limited to S-acylation and provides no548
information on the lipid. MTCC approaches, in contrast, are unbiased and wide in scope. Only549
proteins dynamically modified during the incubation time with the analogue will be tagged and550
therefore identified  whilst this can be a potential limitation, more importantly it offers the551
opportunity for profiling dynamic lipidation through pulse-chase approaches. These technologies552
have dramatically increased our appreciation of the extent of protein lipidation in parasites and553
demonstrate that targeting these modifications could have therapeutic value. The identification of554
small molecule inhibitor scaffolds that inhibit protozoan acyl transferases with high selectivity over555
the corresponding human enzymes is an important consideration for the development of therapies.556
In the case of Plasmodium and Leishmania, pyridyl, 1,3,4-oxadiazole containing 5-chlorophenyl, and557
peptidomimetic based scaffolds show promising characteristics and good cellular efficacy, including558
against liver stage malaria parasites. In the case of Trypanosoma, pyrazole sulphonamides,559
thiazolidinone and benzomorpholinone inhibitors are potent antiparasitic compounds; however, BBB560
permeability and selectivity needs to be further improved to increase their efficacy against stage 2 of561
T. brucei infection. Bringing together lipid profiling technologies and medicinal chemistry efforts,562
MTCC platforms in particular have been successfully used to demonstrate the on-target mode of563
action of NMT inhibitors in live parasites.564
Evidence from analytical tools has accumulated to the point where S-acylation must be considered a565
major regulatory pathway in all eukaryotes (Resh, 2016). The enzymes involved in removal of this566
modification come from the superfamily of serine hydrolases, and selective small molecule inhibitors567
are available for some of these enzymes. Their inhibition can lead to interesting and unexpected568
phenotypes, as mentioned above, and further characterisation of their apparently broad substrate569
scope and complex localisation will be important in validating them as potential drug targets. In570
contrast, the diverse class of protein S-palmitoyl transferases (PATs), including >20 genes in humans,571
has yet to yield to small molecule inhibitor discovery, and the chemical tools available for PATs are572
effectively non-existent. Indeed, the continued use of 2-BP due to its commercial availability is to573
greatly compound the challenges of the field due to the exceptional promiscuity of this molecule, as574
noted above. Robust and widely-applicable CRIPSR-Cas gene-knockout approaches will be an575
important enabling tool to unpick the roles of PATs in parasites and in the host, but the discovery of576
cell-active inhibitors selective for the class, or for members of the class, would be transformative for577
the field, and should be pursued as a high priority.578
In contrast, the scope for NMT as a target in eukaryotic pathogens is very clear, and may be very579
broad, as recently demonstrated for helminths (Galvin et al., 2014). The availability of multiple580
potent inhibitor series and powerful tools to analyse PTMs in living systems greatly enhances the581
opportunities for drug development against this target. With the exception of T. brucei, which is582
rapidly killed by NMT inhibition due to its exceptional reliance on myristoylation-dependent583
trafficking, NMT inhibition has a quite extended mode of action. This is hypothesised to be due to an584
indirect dependence on protein degradation: myristoylated proteins that were present prior to585
inhibition will typically need to undergo some degree of degradation in order for inhibition of co-586
translational myristoylation to impact viability. Careful consideration of compound uptake in cells,587
distribution/pharmacokinetics and pharmacodynamics (the dynamics of target engagement) will be588
required to realise the potential of NMT inhibitors as antiparasitic agents, and research towards this589
objective continues in our labs, in collaboration with other research groups.590
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Figure 1.Workflow of the acyl biotin exchange (ABE) approach to identify S-acylated proteins. Free
thiols in protein lysates are blocked with N-ethyl maleimide followed by selective cleavage of
thioesters using hydroxylamine and labelling of the liberated thiols with HPDP-biotin. Next, a typical
proteomics workflow that includes affinity enrichment of the biotinylated proteins, proteolytic
digest, and analysis of the peptide fragments by mass spectrometry enables the identification of S-
acylated proteins. A control sample that still contains the intact thioesters and therefore no biotin
tags facilitates the identification of non-specifically enriched proteins.
Figure 2. A)Workflow of metabolic tagging with click chemistry (MTCC) approach. Analogues of the
investigated PTM (e.g. compounds shown in B) are fed to cells and incorporated into the
corresponding proteins. After cell lysis, an affinity tag is attached to the analogue using bio-
orthogonal CuAAC. Affinity enrichment followed by tryptic digestion and analysis of the peptide
fragments by mass spectrometry facilitates the identification of proteins that exhibit this specific
PTM. B)Myristic and palmitic acid probes that have been applied in an MTCC approach in protozoan
parasites.
Figure 3. A) Comparison of P. falciparum proteins identified via ABE and MTCC (with 17-ODYA (4);
workflows: cf. Fig. 1 and 2A) techniques in the study of Jones et al. B) Comparison of T. gondii
proteins identified in the studies of Caballero et al. and Foe et al.. which used a complementary ABE
approach (cf. Fig. 1) and a global analysis of 17-ODYA (4) tagged proteins in the presence and
absence of hydroxylamine, respectively. Total rather than high confidence hits were used in each
case. C) Comparison of the 321 putative P. falciparum palmitoyl proteins (from Jones et al., 2012)
that have T. gondii orthologues with putative T. gondii palmitoyl proteins (Caballero et al., 2016; Foe
et al, 2015). D) Likely dual acylated proteins in P. falciparum. (Supplementary Table S1). Numbers in
the Venn diagrams may differ slightly from those reported in the primary literature due to revisions
in sequence databases over time, ID mapping issues (e.g. between the two Tg species analysed in B),
and, in diagram C, the manner in which the protein inference problem has been handled; most
proteomic analyses group proteins when they cannot be distinguished by mass spectrometry, but
here each protein was treated independently.
Figure 4. A) YnMyr-CoA crystallised in the Myr-CoA binding pocket of PvNMT (PDB: 2YNC). B)
YnMyr (1) is incorporated into proteins via both amide (NaOH-insensitive) and ester (NaOH-sensitive)
linkages. Proteomics revealed the base-sensitive incorporation to be on GPI anchored proteins. C)
Dose-response of YnMyr (1) incorporation upon co-incubation with NMT inhibitor DDD85646 (19). In-
gel fluorescence read-out (graph on the right: quantification of fluorescence intensity) following the
workflow shown in Fig. 2A and includinga base-treatment step to remove GPI anchor labelling. Figure
adapted from: (Wright et al., 2014).
Figure 5. A) Comparison of MTCC (workflow: Fig. 2A) with palmitate analogue YnPal (2) and myristate
analogue YnMyr (1) in bloodstream form (BSF) T. brucei. B) In-gel fluorescence read-out of the effect
of NMT inhibition with DDD85646 (19) on YnMyr (1) labelling in BSF parasites. YnMyr (1)
incorporation into GPI anchored proteins, such as the VSG (Variant Surface Glycoprotein; indicated
by arrow), is unaffected but incorporation into N-myristoylated proteins drops. Figure adapted from
(Wright et al., 2016).
Figure 6. A) Comparison of T. brucei proteins identified via ABE and MTCC (with YnMyr (1);
workflows: Fig. 1 and 2A) techniques in the studies of Emmer et al. and Wright et al. B) Comparison
of high confidence T. bruceimyristoyl proteins that have T. cruzi orthologues with high confidence T.
cruzimyristoyl proteins. C) Comparison of high confidence T. bruceimyristoyl proteins that have L.
donovani orthologues with high confidence L. donovanimyristoyl proteins. Numbers in the Venn
diagrams may differ slightly from those reported in the primary literature due to revision of sequence
databases over time and, in B and C, the manner in which the protein inference problem has been
handled (see Fig. 3). D) Candidate dual acylated proteins in T. brucei (high confidence NMT substrates
also identified by both palmitoyl proteome studies (Emmer et al., 2011; Wright et al., 2016). E) High
confidence N-myristoyl proteins conserved across all three organisms. (Supplementary Table S2).
Figure 7. Studying protein N-myristoylation in Leishmania parasites. YnMyr (1) was incubated with
parasites, in some cases in the presence of NMT inhibitors 19 or 19a. Following incorporation into
proteins, click chemistry was used to append a fluorophore or affinity handle; in-gel fluorescence
analysis (A) provided a simple read-out for inhibitor activity in cells, and quantitative chemical
proteomics (B) enabled the identification of proteins and lipidation sites. This study also compared
different life stages of the parasite: promastigotes (Pro.) and amastigotes (Am.). MG = protein
contains an N-terminal glycine (possible NMT substrate). Figure adapted from (Wright et al., 2015).
Figure 8. A) Superposition of the crystal structures of the quinoline (5) and the 1,2,4-oxadiazole (16)
based inhibitors in complex with PvNMT (PDB code: 4A95, compound 5, orange; 4B14, compound 16,
blue) and biological activity of the quinoline compounds 5 and 6 against PvNMT,HsNMT1, andHsNMT2
(Yu et al., 2015). B) Superposition of the crystal structures of aminoacylpyrrolidine 7, piperidinylindole
8, and the corresponding hybridization product 9 in complex with LdNMT (PDB code: 4cgl, compound
7, green; 4cgn, compound 8, blue; 4cyo, compound 9, red) and biological activity of 7, 8, and 9 against
LdNMT, HsNMT1, and antiparasitic activity against extracellular amastigotes of L. donovani (Hutton et
al., 2014). The piperidinylindole 8 and the hybridization product 9 show an interaction of a basic centre
with the C-terminal carboxylate of NMT. Additionally, all compounds show interactions with a set of
aromatic amino acids.
Figure 9. A) Biological activity against PfNMT and HsNMT1 and antiparasitic activity against P.
falciparum 3D7 of NMT inhibitors derived from R0-09-4609 (10) by scaffold-hopping. The
superposition of the crystal structures of the benzo[b]furan based derivative 12 and the scaffold
simplified analogue 16 in complex with PvNMT indicates competitive binding of the inhibitors with
the peptide substrate (PDB code: 4UFV, compound 12, orange; 4B14, compound 16, blue) (Yu et al.,
2015). B) Crystal structure of the N-myristoylated inhibitor product in complex with PvNMT. The
peptidomimetic inhibitor (18) is shown in orange and the myristic acid moiety in blue (Pdb code:
4c7h). Additionally, 20% of the electron density corresponds to the CoA by-product (in red),
providing structural evidence for a product complex in NMT for the first time (Olaleye et al., 2014).
Figure 10. A) Biological activity against TbNMT and HsNMT1, antiparasitic cell activity against
bloodstream form T. brucei parasites, and BBB permeability (B:B = brain to blood ratio, ND = not
determined) of TbNMT lead inhibitors (Brand et al., 2014; Spinks et al., 2015). B) Superpositions of
the crystal structures of DDD85646 (19) (PDB code: 2WSA, red) with, respectively, lead compounds of
the thiazolidinone (21) (PDB code: 5AG6, green) and benzomorpholinone (22) (PDB code: 5AGE, blue)
series in complex with the TbNMT surrogate LmNMT reveal that the two new inhibitor classes (21
and 22) exhibit a different binding mode than the sulphonamides (19) (Spinks et al., 2015).










